Nivalis Therapeutics Inc (NASDAQ:NVLS) insider Value Fund L. P. Biotechnology bought 78,858 shares of the stock in a transaction that occurred on Friday, May 19th. The stock was acquired at an average price of $2.30 per share, for a total transaction of $181,373.40. The acquisition was disclosed in a filing with the SEC, which can be accessed through the SEC website.
Nivalis Therapeutics Inc (NASDAQ:NVLS) traded up 0.43% during midday trading on Friday, reaching $2.32. 63,750 shares of the company’s stock traded hands. Nivalis Therapeutics Inc has a 52-week low of $2.00 and a 52-week high of $9.35. The firm’s market cap is $36.42 million. The firm’s 50-day moving average is $2.50 and its 200 day moving average is $2.95.
Nivalis Therapeutics (NASDAQ:NVLS) last issued its earnings results on Monday, February 13th. The biotechnology company reported ($0.50) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.55) by $0.05. During the same quarter in the prior year, the company posted ($0.42) earnings per share. Equities research analysts expect that Nivalis Therapeutics Inc will post ($1.16) earnings per share for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: “Value Fund L. P. Biotechnology Buys 78,858 Shares of Nivalis Therapeutics Inc (NVLS) Stock” was originally posted by Mideast Time and is the property of of Mideast Time. If you are reading this article on another website, it was stolen and republished in violation of U.S. and international copyright & trademark law. The legal version of this article can be viewed at https://www.mideasttime.com/value-fund-l-p-biotechnology-buys-78858-shares-of-nivalis-therapeutics-inc-nvls-stock/1708468.html.
A number of equities research analysts recently weighed in on the stock. Zacks Investment Research lowered shares of Nivalis Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, May 5th. Cowen and Company restated a “hold” rating on shares of Nivalis Therapeutics in a report on Wednesday, April 19th. Finally, Vetr lowered shares of Nivalis Therapeutics from a “hold” rating to a “sell” rating and set a $2.50 target price on the stock. in a report on Monday, February 27th. One analyst has rated the stock with a sell rating, five have given a hold rating and two have given a buy rating to the company. The company presently has an average rating of “Hold” and an average target price of $7.68.
Several hedge funds and other institutional investors have recently modified their holdings of NVLS. Spark Investment Management LLC purchased a new position in shares of Nivalis Therapeutics during the third quarter valued at about $145,000. Perceptive Advisors LLC purchased a new position in shares of Nivalis Therapeutics during the fourth quarter valued at about $274,000. Endurant Capital Management LP increased its position in shares of Nivalis Therapeutics by 29.8% in the third quarter. Endurant Capital Management LP now owns 85,412 shares of the biotechnology company’s stock valued at $694,000 after buying an additional 19,629 shares in the last quarter. Vanguard Group Inc. increased its position in shares of Nivalis Therapeutics by 104.7% in the first quarter. Vanguard Group Inc. now owns 411,229 shares of the biotechnology company’s stock valued at $1,201,000 after buying an additional 210,325 shares in the last quarter. Finally, Sphera Funds Management LTD. purchased a new position in shares of Nivalis Therapeutics during the third quarter valued at about $1,664,000. Hedge funds and other institutional investors own 75.85% of the company’s stock.
Nivalis Therapeutics Company Profile
Nivalis Therapeutics, Inc is a pharmaceutical company. The Company focuses on the discovery and development of product candidates for patients with cystic fibrosis (CF). Its drug candidate portfolio consists of multiple compounds, which are designed for oral, intravenous (IV) or inhaled administration.
Receive News & Ratings for Nivalis Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nivalis Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.